Resmed's (ASX:RMD) continuous positive airway pressure (CPAP) devices andmasks treat sleep apnea.
CPAP has long been thegold standard for treating obstructive sleep apnea (OSA), and ResMed is theleading global supplier.
But as of today, ResMed shares have fallen from $40.13 to $23.51,which would be 71% profits for the trade if it recovers back to $40.13.
The sell-off was triggered by disappointing gross margins andgrowing investor concerns about competition from a new wave of GLP-1weight-loss drugs.However, GLP-1 facesseveral headwinds, including supply constraints, lagging real-world efficacy,side effects, low drug compliance, high costs, and a possible lack of insurancecoverage.
Its attractive valuation currently outweighs the risks it faces.This is a great buyingopportunity for me, bought (ASX:RMD) today.
(20min delay)